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ABSTRACT 
Background:  Intensity-modulated radiation therapy (IMRT) has been employed as a 
precision radiation therapy with higher conformity to the target. Although clinical outcomes 
have been reported for many investigations,	 detailed treatment planning results have not been 
mentioned so far. The aim of this study was to evaluate the dose specifications of our IMRT 
treatment plans for locally advanced prostate cancer. 
Methods: Seventy-seven clinically applied IMRT plans	 treated between September 2003 and 
December 2005, in which patients were irradiated 78Gy in the prone position, were 
retrospectively analyzed. Dosimetric data outputted from dose volume histograms	 were 
evaluated in detail. 
Results: The mean dose ±	 standard deviation, homogeneity index and conformity index  to 
the planning target volume (PTV) were 78.3 ± 0.7 Gy (100.4 ± 0.9%), 13.7 ± 3.0, and 0.83 ± 
0.04, respectively. For the clinical target volume, the mean dose was 80.3 ± 0.7Gy (102.9 ± 
0.9%)．The V40Gy, V60Gy, and V70Gy of the rectal wall were 58.3 ± 2.8, 29.6 ± 2.7, and 
15.2 ± 3.0%, respectively. Planning difficulties were encountered in patients whose bowels 
were displaced downward, as constraints imposed by the bowel position altered the dose 
index of the PTV. In many cases, additional bowel optimization parameters were required to 
satisfy constraints for organs at risk. However, major deviation could be avoided by inverse 
planning with computer optimization. 
Conclusion: IMRT allowed to create acceptable and practical treatment  plans for locally 
advanced prostate cancer. Reports regarding detailed dosimetric evaluations are mandatory to 
interpret clinical outcomes in the future. 
 
Mini Abstract 
Detailed dosimetric data on IMRT plans for locally advanced prostate cancer were reported, 
which is mandatory for interpretation of clinical outcomes as well as creating planning 
protocols in the future. 
 




   Intensity-modulated radiation therapy (IMRT) has been employed as a precision 
radiation therapy offering higher conformity to the target1. IMRT can create complicated dose 
distributions achieving a dose escalation to the target volume and dose reduction of organs at 
risks (OAR) adjacent to the target using a computer optimization. Many clinical 
investigations were reported dosimetric and clinical advantages of IMRT for prostate 
cancers2-7, head-and-neck tumors8,9, brain tumors10-12, gynecologic tumors13-15 and so forth.  
   Especially in the prostate cancer, its advantage is distinctive and widely applied as 
a routine clinical practice, and better clinical outcomes had been reported. However, details of 
treatment planning results were not mentioned in existing articles, which will make it difficult 
to compare outcomes among different institutions and to derive an optimal treatment planning 
policy from planning-outcome comparison studies. Because IMRT plans have essentially 
inhomogeneous dose distribution, it is very difficult to grasp the big picture of the treatment 
plans of IMRT based on some representative dosimetric index values alone such as D95. 
Therefore, this study was aimed to reveal the dose specifications of our routine IMRT 
planning protocol for locally advanced prostate cancer as well as to compare to our previous 
3D-CRT methods16. 
 
MATERIALS AND METHODS 
Patient characteristics 
   Between September 2003 and December 2005, 85 patients with T3N0M0 prostate 
cancer, classified based on the 2002 definition of the International Union against Cancer, 
were consecutively treated by IMRT at our institution. Of those, eight cases were excluded 
from the analysis because of the following reasons. In five of the patients, the prescribed dose 
was reduced from 78 to 66–74 Gy due to diabetes mellitus, previous irradiation adjacent to 
the prostate, or a history of surgical management of rectal cancer; two other patients were 
irradiated using a setup position or port arrangement different from the routine protocol, and 
one patient had a huge atonic neurogenic urinary bladder and required a different planning 
concept to the bladder. Therefore, the present study was finally conducted on remaining 77 
patients with T3N0M0 prostate cancer treated by standard IMRT plans. These patients were 
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treated in the prone position and delivered 78 Gy to the target. Their characteristics are 
indicated in Table 1. 
 
IMRT Planning protocols 
   Patients were immobilized in the prone position using a thermoplastic shell (Hip 
Fix system; Med-Tec Inc., Orange City, IA, USA), which extended from mid-thigh to the 
upper third of the leg in combination with a vacuum pillow (Vac-Lok system; Med-Tec Inc.) 
and a leg support. Planning computed tomography (CT) images were acquired using a CT 
simulator (CTS-20; Shimadzu, Kyoto, Japan) with a 5-mm slice thickness. Patients were 
instructed to void the urinary bladder and rectum about 1–1.5 h before the CT scan according 
to the patient’s particular condition. Setup error was evaluated based on bony structures with 
liniacography (LG). Offline systematic error correction was performed with sequential five 
LG obtained in the first five irradiation, and weekly LG was taken for a setup verification. 
 All plans were carried out using 15-MV photon beams delivered by a Clinac 2300 
C/D (Varian Medical Systems, Palo Alto, CA, USA) with a 40-leaf pair of multileaf 
collimators of 1-cm thickness. Treatment plans were created using an Eclipse-Helios system 
(Ver. 7; Varian Medical Systems, Palo Alto, CA, USA). The final dose distributions were 
calculated using a pencil beam convolution algorithm with a 5 mm by 5 mm calculation grid 
size. The modified Batho was applied for heterogeneity correction. 
   The prostate, seminal vesicles, rectal outer wall, bladder outer wall, small bowel, 
and large bowel were contoured. A clinical target volume (CTV) was created based on the 
prostate and seminal vesicles, which were contoured with reference to magnetic resonance 
images	 in most of the patients. The proximal two-thirds of the seminal vesicles were included 
in the CTV for T3a cases, and the entire seminal vesicles were included in the CTV for T3b 
patients. Inclusion of the seminal vesicles in the CTV resulted in larger CTVs in the current 
series than in the IMRT protocol used in a previous study, in which only the prostate was 
irradiated16. Margins for the planning target volume (PTV) were added to the CTV according 
to the following 3D setting: 9-mm margins universally, except for a 6-mm margin posteriorly 
(for the direction to the rectum) and 10 mm superiorly (for the caudal direction). The rectal 
wall (RECT_W) was generated using the extract wall function of the treatment planning 
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system (TPS) applying a 4-mm thickness. The existing RECT_W was uniform, ranging from 
10 mm below the apex of the prostate to 10 mm above the tips of the seminal vesicles. The 
bladder wall (BLAD_W) was generated in the same manner with a 4-mm thickness. The PTV 
was divided into two components, with and without rectal overlap, for use in computer 
optimization. When the overlapping area of the PTV and bowels was large and caused 
difficulties in optimization, the PTV was further divided.  
   A five-field dynamic multileaf collimator technique was used for IMRT beam 
delivery. Gantry angles were 0, 75, 135, 225, and 285 degrees. Inverse treatment planning by 
computer optimization was conducted with the Helios system. The inverse optimizations were 
performed with the aim of fulfilling the planning goals establish in our planning protocol. The 
treatment planning goals to be achieved in the final dose distribution are listed in Table 2. Not 
only these hard constraints but also the following soft constrains were taken into account in 
accepting the final dose distribution, after fine adjustment of a normalization value. (1) The 
anterior rectal wall should receive 90–100% of the prescribed dose; the 95% isodose line 
usually lies between the anterior border of the rectal wall and the posterior border of the PTV. 
(2) There should be no significant hot spots outside the PTV. (3) The 50% isodose line of the 
prescribed dose should generally not exceed the posterior wall of the rectum. These same 
constraints were also applied in the previous 3D-CRT plan used in our institution, in which 
patients were irradiated with 74 Gy. When the plan did not match the OAR constraints despite 
adjustments of the optimization parameters, PTV dose coverage was sacrificed to give higher 
priority to the OARs. 
 
Analyses of dose statistics 
   Planning data were analyzed using the outputs from the dose-volume histograms 
(DVH) generated by the TPS. D95 (D99) was defined as the percentage of the prescribed dose 
covering 95% (99%) of the volume. V90 was the percentage volume that received at least 
90% of the prescribed dose. V40Gy was defined as the percentage volume that received at 
least 40 Gy. The dose inhomogeneity of the PTV was defined using the following equation: 
Homogeneity index (HI) = (D5 − D95)/mean dose × 100. Dose conformity to the PTV was 
calculated as the conformity index (CI) advocated by van’t Riet17: CI = 
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(V95PTV/VPTV) × (V95PTV/V95BODY). Here, V95PTV is the V95 of the PTV, VPTV is the volume 
of the PTV, and V95BODY is the body volume covered by 95% of the prescribed dose. 
   The patients were divided into two groups based on anatomic conditions. Group 
B- consisted of patients who did not need optimization constraints for the bowel, because 
either no or only a very small volume of bowel was included in the irradiated field. Group B+ 
comprised patients who required additional bowel optimization parameters to satisfy the final 
dose constraints. Statistical calculations were performed with PRISM 4 software (GraphPad 
Software, San Diego, CA, USA). 
 
RESULTS 
Treatment planning  
   A typical dose distribution in the trans-axial plane is shown in Figure 1. Figure 2 
illustrates the DVH, in which the mean and standard deviations of the PTV, RECT_W, and 
BLAD_W are indicated. Target doses statistics are summarized in Table 3. The mean dose 
(mean ± standard deviation) to the PTV was 78.3 ± 0.7 Gy (100.4 ± 0.9%), with a maximum 
dose of 84.7 ± 0.8 Gy (108.6 ± 1.0%). The V90, D95, and D99 were 97.3 ± 2.5, 92.4 ± 2.9, 
and 86.7 ± 5.6%, respectively. The HI was 13.7 ± 3.0, and the CI was 0.83 ± 0.04. For the 
CTV, the mean dose was 80.3 ± 0.7 Gy (102.9 ± 0.9%), and the V90, D95, and D99 were 
99.9 ± 0.4, 98.7 ± 1.2, and 97.0 ± 2.3%, respectively. 
   Plan normalization values were adjusted to meet the dose constraints for the OAR. 
The doses to the RECT_W and BLAD_W are summarized in Table 4. The V40Gy, V60Gy, 
and V70Gy of the RECT_W were 58.3 ± 2.8, 29.6 ± 2.7, and 15.2 ± 3.0%, respectively. The 
V40Gy and V70Gy of the BLAD_W were 41.6 ± 10.8 and 20.6 ± 5.1%, respectively. 
The V65Gy of the large bowel exceeded 0.50 ml in 13 patients (0.51–2.11 ml). However,  
V65Gy exceeded 1.0 ml was  observed in only one patient  (2.11 ml). The V60Gy of the 
small bowel >0.50 ml was observed in five patients (0.51–1.07 ml), but reached 1.0 ml in 
only one patient. 
  If the initial goals could not be satisfied, the optimization parameters were relaxed to meet 
the clinical requirements; to meet the rectal wall constraints, the PTV coverage was sacrificed. 
While treatment planning goals for the OAR were achieved in most cases (Table 5), PTV 
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coverage could not be preserved in several patients presenting with anatomical difficulties. 
 
Impact of the bowels on target coverage 
   Difficulties were encountered in treatment planning for patients whose bowels 
were displaced downward. Figure 3	 indicates the differences in the doses administered to the 
target volumes between the two groups. Forty-eight patients were classified to the  group  B+, 
where additional optimization parameters for the bowels were needed, while 29 cases were 
assigned to the group B-. For the PTV, the D95, V90, and D99 in group B- versus group B+ 
were 93.7 ± 1.2 vs. 91.5 ± 3.3% (p = 0.0006), 98.6 ± 1.1 vs. 96.6 ± 2.8% (p = 0.0003), and 
89.6 ± 2.2 vs. 84.9 ± 6.3% (p < 0.0001), respectively. The values in the group B- were 
significantly higher than those in the group B+. Significant differences in HI and CI were also 
observed. On the other hand, there was no significant difference in the mean dose of the PTV 
and CTV, or in the D95 of the CTV between the groups. 
 
DISCUSSION 
   Intensity-modulated radiation therapy (IMRT) has been employed as a precision 
radiation therapy with higher conformity to the target. Although clinical outcomes have been 
reported for many investigations, results of treatment planning have not mentioned in detail so 
far. Therefore, the aim of this study was to evaluate the dose specifications of our IMRT 
treatment  plans for locally advanced prostate cancer. 
   In an Australian study reported by Skala et al18, three institutions created IMRT 
plans for their patients with prostate cancer using the same contours and dose constraints. 
While the final dose constraints could be satisfied without great difficulty, there were large 
differences in the DVH curves of the OAR. However, determination of inter-institutional 
homogeneity was incomplete due to a lack of detailed information regarding the planning 
concept. In the present study, clinical plans were designed at a single institute by three 
radiation oncologists and five medical physics personnel. Homogeneous plans could be 
achieved within the defined soft and hard constraints. 
   The process of IMRT treatment planning, in which the dose distribution is adjusted 
to achieve a balance between targets and OARs, differs from that of conventional 
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radiotherapy planning. In IMRT plans, the dose distribution is in essentials not homogeneous; 
this is not the case for 3D-CRT plans, which are difficult to adapt because they consist solely 
of a prescribed dose determined using simple methods that have been universally adopted in 
conventional radiotherapy, e.g., the point dose to the isocenter. Discrepancies between the 
“official” prescribed dose of IMRT plans and that of 3D-CRT plans occur not only in the 
inter-institutional variation but also in the intra-institutional variation. The PTV mean doses 
of IMRT plans in the present study (CTV = prostate + whole or 2/3 of seminal vesicles) and 
3D-CRT plans in a previous analysis ( CTV = prostate alone ) were 100.4 ± 0.9 and 99.5 ± 
0.3%, respectively, while the corresponding CTV values were 102.9 ± 0.9 and 100.7 ± 0.7%, 
respectively16.  
Unlike the conventional radiation treatment planning with the dose prescription to 
the isocenter, the final dose distribution of IMRT has larger variation because inverse 
planning deviates from the optimization constraints; that is, the dosimetric values determined 
by the planner (e.g., prescribed dose) is one of several optimization parameters. 
Normalization with the D95 of the PTV overlapping the OAR may cause large differences in 
the PTV mean dose, depending on the volume ratio included in the OAR, and may increase 
treatment inhomogeneity. In contrast, the application of multiple dose constraints as applied 
in our protocol results in rather homogeneous mean doses to the target. In designing our 
planning protocol for prostate IMRT, we decided to give higher priority to avoid potential 
dose escalation and larger variation in the mean dose to the target caused by the D95 dose 
prescription. Therefore, our 78 Gy plan was defined as plans satisfying the 
previously-described soft and hard constraints, which resulted in very small variations in the 
mean doses to both the CTV and the PTV as indicated in Table 3.	 In our planning protocol, 
the coverage, homogeneity, and conformity were sacrificed to spare the bowels, while the 
CTV dose was maintained. In other words, the PTV dose was decreased to provide adequate 
clinical optimization. IMRT plans often require this kind of compromise to avoid extreme 
deviations. 
 In this study, rectal radiation doses were analyzed based on relative volumes, using 
software designed for the TPS. Munbodh et al. analyzed the radiation dose on the rectum 
surface to identify indicators of late rectal toxicity19. However, this approach poses several 
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clinical difficulties such as necessity of the special in-house software. In contrast, evaluating 
the dose to the OAR based on the absolute volume appears to result in less inter-institutional 
deviation. Thus, details of rectal DVH analyses based on a uniform delineation and absolute 
volumes may serve as a useful alternative indicator. In the meantime, it is important to create 
standard DVH models and make them available for clinical evaluation. 
   Several guidelines or recommendations for documenting and reporting IMRT 
plans have been published20,21. After achieving homogeneity in terms of target delineation and 
optimization, detailed reporting and analysis are indispensable in the interpretation and 
comparison of clinical outcomes21. This is also true within a single institute, where a thorough 
review of treatment planning results is essential to evaluate clinical outcome. The precise and 
quantitative evaluation of treatment plans may contribute to the development of new 
treatment protocols or guidelines	 in the future. 
   Recently,  several image-guided radiotherapy (IGRT)  techniques have introduced 
in IMRT for prostate cancer. Prostate-based online error correction can be performed using 
fiducial marker, CT on rails, cone beam CT, ultrasound or electric magnetic signals. This 
article was based on rather early IMRT cases for prostate cancers in our institute, setup error 
correction was performed with offline method, the PTV margin is comparatively not so small. 
Decreased CTV to PTV margin is expected to toxicity reduction, and have make possible 
higher dose delivery to prostate. It’s clinical impact have not established yet, clinical 
application requires careful consideration to avoid decreased tumor control22.  
   In conclusion, planning outcomes of a clinical IMRT planning protocol for 
prostate cancer	 were evaluated. Several dose constraints for PTV and OAR were sufficient to 
maintain planning homogeneity. In patients with downward displacement of the small and 
large bowels, additional optimization parameters were often required. Although this sacrificed 
PTV coverage, major deviations from the constraints were avoided due to computer 
optimization. The precise evaluation of clinical plans, as conducted in the present study, is 
indispensable to understanding the inter- and intra-institutional differences in clinical 
outcomes. This analysis provides an important basis upon which to design treatment planning 
protocols as well as interpreting clinical outcomes of the current protocol in the future.  
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Fig. 1  Typical dose distributions in the trans-axial (a) and sagittal (b) plane. 
(a)      
(b)     
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Fig. 2  
Dose-volume histograms (DVHs) indicating mean and standard deviation of the (a) planning 
target volume (PTV), (b) rectal wall (RECT_W), and (c) bladder wall (BLAD_W). 
 
 
Fig. 3  
The differences of index 
values in the doses 
administered to the target 
volumes. IMRT plans 
were stratified whether 
additional optimization 
parameters for the 
bowels were needed 
(group B+, n = 48) or not 





Table 1.  Patient characteristics 
Clinical Stage   
    T3aN0M0 : n=52   
    T3bN0M0 : n=25   
 median range 
Age 72  (56—80) 
   
Prostate volume ( ml ) 27.4 (13.7—52.8) 
CTV volume ( ml ) 37.7 (20.6—64.6) 
PTV volume ( ml ) 120.9 (73.0—176.5) 
   
Rectal wall volume ( ml ) 36.2 (21.2—72.4) 
Bladder wall volume 
( ml ) 78.9 (35.4—145.7) 
   
Large bowel* ( ml ) 13.0 (0.0—94.1) 
Small bowel* ( ml ) 0.0 (0.0—88.2) 
*the volume involved in radiation field 
 
 
Table 2.  Summary of planning goals 
Structure 	  Constraint (preferable) 
PTV D95 ≥ 90 % (≥ 95 %) 
 V90 ≥ 96 % (≥ 98 %) 
 Max ≤ 110 % 
RECT_W V40Gy ≤ 65 % (≤ 60 %) 
 V60Gy ≤ 35 % (≤ 30 %) 
 V70Gy ≤ 25 % (≤ 20 %) 
 V78Gy < 1 % 
BLAD_W V40Gy ≤ 65 % (≤ 60 %) 
 V70Gy ≤ 35 % 
Bowel_L V65Gy ≤ 1.0 ml (≤ 0.5 ml) 
Bowel_S V60Gy ≤ 1.0 ml (≤ 0.5 ml) 
PTV: planning target volume, RECT_W: rectal wall, BLAD_W: bladder wall, Bowel_S: 
small bowel, Bowel_L: large bowel 
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Table 3.  Results of radiation treatment planning for targets 
	  Prostate CTV PTV 
V90 (%) 100.0 ± 0.0 99.9 ± 0.4 97.3 ± 2.5 
D95 (%) 99.2 ± 0.9 98.7 ± 1.2 92.4 ± 2.9 
D99 (%) 97.8 ± 0.9 97.0 ± 2.3 86.7 ± 5.6 
Minimum dose (Gy) 74.8 ± 1.2 73.2 ± 3.1 60.5 ± 6.3 
Maximum dose (Gy) 84.5 ± 0.9 84.7 ± 0.9 84.7 ± 0.8 
Mean dose (Gy) 80.6 ± 0.7 80.3 ± 0.7 78.3 ± 0.7 
Homogeneity index - - 13.7 ± 3.0 
Conformity index - - 0.83 ± 0.04 
Values are mean ± SD. 
 
 
Table 4.  Results of radiation treatment planning ( OARs ) 
 Rectal wall Bladder wall 
V40Gy (%) 
V60Gy (%) 
58.3 ± 2.8 41.6 ± 10.8 
29.6 ± 2.7 27.4 ± 7.2 
V70Gy (%) 15.2 ± 3.0 20.6 ± 5.1 
Values are mean ± SD. 
 
 
Table 5.  Achievement ratio of treatment planning goals. 
Structure  Achievement of constraint Achievement of preferable 
PTV D95 90% 22% 
 V90 83% 58% 
 Max 99% - 
RECT_W V40Gy 100% 84% 
 V60Gy 100% 56% 
 V70Gy 100% 96% 
 V78Gy 100% - 
BLAD_W V40Gy 100% 97% 
 V70Gy 100% - 
Bowel_L V65Gy 99% 91% 
Bowel_S V60Gy 99% 94% 
PTV: planning target volume, RECT_W: rectal wall, BLAD_W: bladder wall, Bowel_S: 
small bowel, Bowel_L: large bowel 
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